Emerson Process Management (St. Louis, MO) has been  chosen to automate the first Chinese plant to produce monoclonal antibody  drugs. The plant, owned by Shanghai CP Guojian Pharmaceutical Company and  located in the Zhangjiang Hi-Tech Park in Shanghai, China, will have the  largest mammalian cell-culture system in Asia. Monoclonal antibody drug  production is expected to begin in August of this year.

  The automation approach will include Emerson’s “PlantWeb”  architecture with Foundation fieldbus instrumentation and the DeltaV digital  automation system. 

  The Emerson solution is intended to meet the  end-user's goal of applying advanced technology to all phases of pharmaceutical  production while keeping costs low, meeting the construction schedule, and  achieving a smooth start-up. Company officials expect to meet international  standards with the products manufactured at this facility.

News

Emerson Process Management (St. Louis, MO) has been chosen to automate the first Chinese plant to produce monoclonal antibody drugs.